2.20
+0.08
(3.53%)
Jun 18 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
| Range | 2.10 - 2.33 |
| 52 week | 1.06 - 6.58 |
| Open | 2.12 |
| Vol / Avg. | 1.56M/1.65M |
| Mkt cap | 7.61M* |
| P/E | - |
| Div/yield | - |
| EPS | -0.03* |
| Shares | 346.02M |
| Beta | - |
| Inst. own | - |
| *GBP |
Events
Apr 11, 2013
Preliminary 2012 Plethora Solutions Holdings PLC Earnings Release
Apr 4, 2013
Plethora Solutions Holdings PLC General Meeting
|
|
Key stats and ratios
| Q2 (Jun '12) | 2011 | |
| Net profit margin | -715.90% | -2570.37% |
| Operating margin | -426.15% | -2331.22% |
| EBITD margin | - | -1408.99% |
| Return on average assets | -388.74% | -368.17% |
| Return on average equity | - | - |
| Employees | 13 | - |
| Carbon Disclosure Rating | - | - |
Address
Fourth Floor, 233 High Holborn
LONDON, ENG WC1V 7DN
United Kingdom - Map
+44-20-30775400 (Phone)
+44-20-30775440 (Fax)
LONDON, ENG WC1V 7DN
United Kingdom - Map
+44-20-30775400 (Phone)
+44-20-30775440 (Fax)
Website links
External links
Analyst Estimates - BusinessWeek
Options - MarketWatch
Research Reports - Reuters
Director Dealings - Yahoo Finance
Discussion Group - Google Finance
Advertisement
Description
Plethora Solutions Holdings plc is is a specialty pharmaceutical company engaged in the development and sale of drugs and medical devices for the diagnosis, treatment and management of urology, sexual health, gynecology and reproductive health conditions. The Company operates in two segments: Plethora Development and The Urology Co. The Plethora Development segment is engaged in the development of new pharmaceutical products. The Urology Co is the Company�s specialty sales and marketing business engaged in the sale and marketing of pharmaceutical and healthcare products in the United Kingdom and continental Europe. The Company�s product portfolio consists of its generic pharmaceutical products and over the counter (OTC) products. Its PSD502 is a treatment for premature ejaculation, sometimes referred to as (PE). As of December 31, 2011, the Company�s subsidiaries include Plethora Solutions Limited, The Urology Company Holdings Limited and The Urology Company Limited.
Officers and directors
| J. Ronald Openshaw | Chief Executive Officer, Chief Financial Officer, Company Secretary, Executive Director | |
| Michael G. Wyllie Ph.D. | Chief Scientific Officer, Executive Director | |
| James Mellon | Interim Non-Executive Chairman of the Board |